GSK to develop plant-based COVID-19 vaccine with Canada’s Medicago – ZAWYA

GSK to develop plant-based COVID-19 vaccine with Canada’s Medicago – ZAWYA

GSK to develop plant-based COVID-19 vaccine with Canada's Medicago | ZAWYA MENA Edition HomeLifeHealthArticleGSK to develop plant-based COVID-19 vaccine with Canada's Medicago Aim is to make 100mln vaccines available by end-2021    The world's largest vaccine-maker GSK has put its vaccine booster technology to work in a potential new COVID-19 shot, to be developed with a Canadian biopharmaceutical company backed by tobacco company Philip Morris.Rather than developing its own vaccine in the global race to combat the pandemic, GSK has instead focused on contributing its adjuvant technology to at least seven other global companies, including Sanofi SAY.PA and China's Clover. The latest deal, with Canadian firm Medicago, uses plant-based technology that differs from GSK's other coronavirus-partnerships and boosts the London-listed company's chances of finding a successful candidate and scaling production relatively quickly.Rather than developing its own vaccine in the global race to combat the pandemic, GSK has instead focused on contributing its adjuvant technology to at least seven other global companies, including Sanofi SAY.PA and China's Clover. The world's largest vaccine-maker GSK has put its vaccine booster technology to work in a potential new COVID-19 shot, to be developed with a Canadian biopharmaceutical company backed by tobacco company Philip Morris.The latest deal,